Evidence map›Paper›PMID 32355314›Full record

ArticleScientific reports2020

Neurons promote encephalitogenic CD4

Yuki Nakazato, Yuki Fujita, Masamitsu Nakazato, Toshihide Yamashita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yuki NakazatoDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuki FujitaDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masamitsu NakazatoDepartment of Internal Medicine, Division of Neurology, Respirology, Endocrinology, and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Toshihide YamashitaDepartment of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Osaka, Japan. yamashita@molneu.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0003-4559-7018
University of Miyazaki · JPOsaka City University · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by neuroinflammation, leading to demyelination and axonal degeneration. Neuronal excitotoxity mediated by Ca

Indexed as

AnimalsCD4-Positive T-LymphocytesChemokine CCL2Disease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalMaleMiceMice, Inbred C57BLNeurodegenerative DiseasesNeuronsProto-Oncogene Proteins c-fosReceptors, CCR2Tumor Necrosis Factor-alphaCcl2 protein, mouseCcr2 protein, mouseChemokine CCL2Proto-Oncogene Proteins c-fosReceptors, CCR2Tumor Necrosis Factor-alpha

Identifiers

PMID32355314
PMCPMC7192891
OpenAlexW3023022453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.